Back

Managing mavacamten drug interactions in obstructive hypertrophic cardiomyopathy: the role of a clinical pharmacist in a multidisciplinary team

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (5) Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Ms Emilija Katarina Lozo

University Hospital Centre Zagreb, Zagreb (Croatia)

7 More presentations in this session

Presentation thumbnail
Trend of echocardiographic parameters, ventricular-arterial coupling and biomarkers in advanced heart failure outpatients undergoing intermittent therapy with levosimendan
Doctor G. Togni (Bergamo, IT)
Abstract
Presentation thumbnail
Myocardial and metabolic effects of intermittent levosimendan in advanced heart failure
Doctor R. Fernandes Da Silva (Evora, PT)
Abstract
Presentation thumbnail
Echocardiographic and biomarker response to levosimendan cycles in advanced heart failure
Doctor R. Fernandes Da Silva (Evora, PT)
Abstract
Presentation thumbnail
Real-world effectiveness of inclisiran in heart failure patients with coronary artery disease across the ejection fraction spectrum
Doctor A. Cerar (Ljubljana, SI)
Abstract
Presentation thumbnail
Meldonium improves aerobic capability and quality of life in HFpEF patients
Professor K. Trusinskis (Riga, LV)
Abstract

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (5)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources